Skip to main content

Publication, Part of

[MI] Cancer Quality of Life Survey, Invites up to June 2023

Survey

Publication Date:
21 Sep 2023
Geographic Coverage:
England
Page contents

Summary

The Cancer Quality of Life Survey is an ongoing national survey run by the NHS in England. The survey is for people in England who have had a cancer diagnosis, with people invited to complete the survey around 18 months after diagnosis. It has been running since September 2020, with a gradual roll-out to all cancer sites.

The aim of the survey is to find out how quality of life may have changed for people diagnosed with cancer. The survey asks people who have experienced cancer how they are feeling. Their answers will be compared with information about their cancer diagnosis and treatment. This will help the NHS see where care is working well or not so well, and if any new services are needed. It will help the NHS to improve the way it supports people to live as long and as well as possible. The survey is made up of two questionnaires which measure overall health (EQ-5D) and quality of life (EORTC QLQ-C30).

The survey results are reported in an interactive dashboard, including summary score measures and more detailed measures of different aspects of quality of life, including aspects of health (such as mobility), functional categories (such as emotional) and symptoms (such as fatigue). Results are reported by geographies and cancer sites, and with breakdowns by demographic groups.

This release updates the data included in the dashboard, to additionally include data for patients invited from January 2023 to June 2023 and to include response data received up to 7th August 2023. This release provides data for a number of additional broad and detailed cancer types.

Key Facts

46% of people with cancer who received a survey invite responded

equating to 146,193 responses from 320,650 people invited

in England,  for invites sent between September 2020 to June 2023 and to include response data received up to 7th August 2023.

Cancer patients on average scored 74 out of 100, compared to 90 in the general population (adjusted for age and gender)

for an overall health summary score, where higher scores suggest better quality of life

in England, for invites sent between September 2020 and June 2023, including responses up to 7 August 2023 (Overall health summary score, EQ-5D Index) 

Background

The data is presented by combinations of selected:

  • Geographies: England, NHS regions, Cancer Alliances, Integrated Care Boards and Trusts at diagnosis.
  • Cancer sites: 
    • Broad groups: Bone and soft-tissue, Brain and CNS, Breast, Colorectal, Endocrine, Gynaecological, Haematological, Head and neck, Lung, Melanoma, Prostate, Upper gastrointestinal, Urological, Other.
    • Detailed groups: Colon, Rectal, Cervical, Ovarian, Uterine, Other gynaecological, Leukaemia, Multiple myeloma, Non-Hodgkin lymphoma, Other haematological, Oesophageal, Pancreatic, Stomach, Liver and other upper gastrointestinal, Bladder, Kidney and urinary tract, Testicular. 
  • Demographic groups: gender, age at diagnosis, ethnic group, deprivation area and stage at diagnosis.

 

Feedback

Feedback can be sent to: [email protected]. This email address can be used for general enquiries to NDRS. Please do not include sensitive or patient identifiable information.

Last edited: 7 March 2024 2:54 pm